Treatment Access News
CanPrEP Submits Supplemental Recommendations on Truvada for HIV PrEP to pCPA
january 4, 2017
CanPrEP is submitting this letter as a supplement to our previous submission to the pan-Canadian Pharmaceutical Alliance on Truvada (fixed dose oral combination emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) for HIV pre-exposure prophylaxis (PrEP). This supplemental submission is intended to address issues raised in the Canadian Drug Expert Committee (CDEC) final report and recommendations on Truvada as PrEP...